COMMUNIQUÉS West-GlobeNewswire

Acentra Health Earns Fourth Consecutive Recognition on the Washington Business Journal’s Annual ‘Largest Private Companies’ List
30/06/2025
Strategic investments in its solutions and workforce fuel the company’s consistent growth in WBJ’s rankings, earning the No. 43 spot in 2025 MCLEAN, Va., June 30, 2025 (GLOBE NEWSWIRE) -- Acentra Health , a technology [...]
PathAI Receives FDA Clearance for AISight® Dx Platform for Primary Diagnosis
30/06/2025
BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug [...]
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
30/06/2025
Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting request to continue [...]
U.S. Department of Health and Human Services Designates Four Nutrients of Public Health Concern Validating Glucose Health, Inc. (OTC: GLUC) Patent Pending Soluble Fiber-Based Nutrition Formulation
30/06/2025
BENTONVILLE, Ark., June 30, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC), a publicly traded company specializing in diabetic nutrition and soluble fiber-based nutrition products, today commented on the U.S [...]
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
30/06/2025
Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human safety data from 1,929 patient Phase 3 program AUSTIN, Texas, June 30, 2025 (GLOBE NEWSWIRE [...]
Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
30/06/2025
CHATHAM, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company, today announced that it will be added to the broad- [...]
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation
30/06/2025
DUBLIN, June 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. [...]
Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib
30/06/2025
• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plus darolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”), the six-month radiographic progression free [...]
FOXO TECHNOLOGIES INC.’S BEHAVIORAL HEALTH SUBSIDIARY HAS BEEN APPROVED TO RECEIVE SCOTT COUNTY OPIOID ABATEMENT FUNDS
30/06/2025
WEST PALM BEACH, FLORIDA, June 30, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “ Company ”) today announced that its behavioral health subsidiary, Myrtle Recovery Centers, Inc., [...]
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
30/06/2025
Primary objective to determine optimal dosing schedule for a registrational trial Trial builds on recommended Phase 2 dose determined in completed Phase 1 trial Trial benefits from $17.6M award from the Cancer [...]
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
30/06/2025
WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc . (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat [...]
Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index
30/06/2025
CLEVELAND, June 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it was added as a member of the U.S. small-cap Russell 2000 ® Index and the broad-market Russell 3000 ® Index as [...]
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease
30/06/2025
In the Phase 2 MINDFuL trial of XPro ™ in patients with early Alzheimer’s Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary cognitive endpoint [...]
Bimergen Energy Enhances Shareholder Value by Canceling 25.1% of Its Outstanding Common Stock
30/06/2025
Newport Beach, CA, June 30, 2025 (GLOBE NEWSWIRE) -- Bimergen Energy Corporation [ OTCQB: BESS ], (“the Company” or “Bimergen”), a developer of utility-scale battery energy storage projects and an independent power [...]
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
30/06/2025
BridgeBio has received a $300 million upfront payment, strengthening the Company’s balance sheet, and supporting the launch of Attruby ® and ongoing late-stage pipeline programs Transaction monetizes 60% of BridgeBio’s [...]
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
30/06/2025
Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN) There are currently no therapies specifically approved [...]
Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
30/06/2025
First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain Management Market SOLANA BEACH, Calif., June 30, 2025 (GLOBE NEWSWIRE [...]
Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings
30/06/2025
FDA provides supportive feedback on proposed statistical analysis plan for neurofilament biomarker analysis of Clene’s NIH-sponsored Expanded Access Program NfL EAP biomarker analyses to be conducted early in the 4 th [...]
Cuprina Provides Update on Research Studies with Three Leading Education Institutes
30/06/2025
SINGAPORE, June 30, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“ Cuprina ” or “the Company ”), a biomedical and biotechnology company dedicated to the development and commercialization of [...]

Pages